FDA Okays Pfizer's RSV Vaccine ABRYSVO For Adults Aged 18 To 59 At Increased Risk For Disease
23/10 03:00
(RTTNews) - Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration approved ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F or RSVpreF vaccine, for the prevention of lower respiratory tract disease or LRTD caused by RSV in ind...